Arrowhead Q3 FY2022 revenue $32.4M, net loss $72.0M; pipeline progresses

ARROWHEAD PHARMACEUTICALS, INC.

2022-Q3 EPS reported -$0.86 revenue$211,656,000

Q3 FY2022 revenue $32.4M (down 29% YoY); net loss $72.0M ($0.68 loss per share) vs $29.9M loss prior year.
Total cash & investments $582.4M, down from $613.4M at Sept 2021; operating loss $72.9M.
Phase 2 fazirsiran: fibrosis regression in 58%, median 83% reduction in Z-AAT accumulation in liver.
Initiated Phase 1/2a for ARO-MUC5AC and ARO-RAGE; Phase 2 GATEWAY for ARO-ANG3 in HoFH started.
Hired Tracie Oliver as CCO; promoted Patrick O'Brien to COO; formed JV Visirna Therapeutics with Vivo Capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.